CRPC
Metastatic castration-resistant prostate cancer
Advertisement
The data were sourced from a deidentified US-based metastatic prostate cancer clinicogenomic database.
Dr. Spratt reviews the safety and efficacy of relugolix plus RT in patients with localized or advanced prostate cancer.
OS was compared using Cox proportional hazards models with IPTW adjusted for baseline characteristics.
Cohort 4 of the trial is the final dose-escalation phase and will be followed by a dose-expansion phase.
Dr. George delves into research for HRR mutation testing in mCRPC, including strategies for earlier testing after diagnosis.
The open-label VISON study randomly assigned patients to receive either 177Lu-PSMA-617 plus SoC or SoC alone.
A total of 488 patients received an average of 2 cycles of 225Ac-PSMA RLT between January 2016 and May 2023.
Patients had previously received an androgen blockade with bicalutamide and an alternative AAT with flutamide.
The study analyzed VISION-eligible patients with mCRPC who were classified as TheraP-eligible or ineligible.
The study is the first large-scale report of patients in the United States treated with 177Lu-PSMA-617.
Drs. Barata and Wallis discuss the interaction of age and benefit of treatment intensification in advanced prostate cancer.
Drs. McGregor and Wallis highlight CONTACT-2, the first study of an ICI-based regimen to show improvement in rPFS in PC.
HRQoL was maintained in the niraparib plus AAP arm, and patients experienced minimal side effect bother from treatment.
The enzalutamide group experienced a significant deterioration in mean fatigue changes when compared with the AA group.
Dr. Maha Hussain presented results of the BRCAAway trial in patients with mCRPC who have HRR mutations.
Cabozantinib plus atezolizumab improves rPFS versus second NHT in patients who had progressed on a prior NHT and have mCRPC.
There has been renewed interest in the platinum-based treatment of metastatic castration-resistant prostate cancer.
Researchers noted a lack of research surrounding treatment-related adverse events in these patients.
Drs. Shen and Graff discuss patient outcomes from TITAN and SPARTAN, as well as assessing functional vs chronological age.
PSA levels were decreased by half in 46.9% of patients, and a decline in CTC count occurred 59.1% of patients.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.